Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions, after a weekly, subcutaneous shot from Pfizer was cleared for NHS use. The ...

The Haemophilia Society said it expects NICE's new guidance to be confirmed in March with Altuvoct becoming available in July.

CSL Behring's gene therapy Hemgenix for haemophilia B has been backed for reimbursement in England and Denmark.

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for ...

On World Haemophilia Day, Jens Oltrogge reviews the progress made in treating this rare disorder, which causes those with the disease to bleed because of a lack of sufficient clotting factor ...

CSL Behring has added another major European market to the list of those providing reimbursement coverage of its haemophilia B gene therapy Hemgenix, after agreeing an access deal in Germany. The ...

Anxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Bio to apply a gene-editing approach to the bleeding disorder.

Pfizer has reported that its anti-tissue factor pathway inhibitor marstacimab is effective at reducing bleed rates in patients with haemophilia A and B, working as well as clotting factor ...

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, and are hoping that a newly-approved long-acting drug can ...

Spark and Pfizer's co-developed haemophilia B gene therapy, SPK-9001, has been granted access to the Priority Medicines programme by the EMA.

Actionable insights where business and society intersect and occasionally collide At the Institute for Business in Global Society (BiGS), we are focused on bringing the latest research on the ...